Pretreatment Serum Uric Acid as an Efficient Predictor of Prognosis in Men with Laryngeal Squamous Cell Cancer: A Retrospective Cohort Study

Table 2

Comparison of UA and the UA/Cr ratio in patients with LSCC, stratified according to demographics and clinical characteristics.

	UA		UA/Cr ratio		Cr
	TNM stage
I ()
II ()
III ()
IV ()		<0.05^b,c,d,e,f		<0.05^e		0.463
T stage
T1 ()
T2 ()
T3 ()
T4 ()		<0.05^b,c,d,e,f		<0.05^c,e,f		0.506
N stage
N0 ()
N1 ()
N2 ()
N3 ()		<0.05^b,d		0.313		0.692
Age
<60 ()
≥60 ()		0.033		<0.001		0.015
BMI
<22.94 (413)
≥22.94 (401)		0.685		0.466		0.229
Hypertension
No ()
Yes ()		<0.001		0.087		0.026
Smoking
No ()
Yes ()		0.749		0.636		0.633
Drinking
No ()
Yes ()		0.107		0.010		0.757
Tumour size
≤2 cm ()
>2 cm ()		0.001		0.332		0.183
Operation therapy
Partial laryngectomy ()
Total laryngectomy ()		<0.001		0.213		0.450
Neck dissection
No ()
Yes ()		0.262		0.557		0.070
Tumour subsite
Supraglottic ()
Glottis ()		0.013		0.601		0.007
Subglottic ()		—		—		—

Data are expressed as deviation (SD). The chi-square test and one-way ANOVA were used. UA: uric acid; Cr: creatinine; BMI: body mass index. for the difference between stage I and stage II (1-way ANOVA with the LSD post hoc test). for the difference between stage I and stage III (1-way ANOVA with the LSD post hoc test). for the difference between stage I and stage IV (1-way ANOVA with the LSD post hoc test). for the difference between stage II and stage III (1-way ANOVA with the LSD post hoc test). for the difference between stage II and stage IV (1-way ANOVA with the LSD post hoc test). for the difference between stage III and stage IV (1-way ANOVA with the LSD post hoc test).